Treatment of acute pain of ureteral and biliary colic with naproxen sodium administered by the parenteral route.

Non-steroidal, anti-inflammatory agents (NSAIDs), wellknown inhibitors of prostaglandins, have been used in the treatment of biliary and ureteral pain since the end of the 1970s. The efficacy and tolerance of a new injectable formulation of naproxen sodium in ureteral and biliary pain was investigated in 77 out-patients, observed in an emergency ward, and affected by acute lithiasic symptomatology. Forty-four patients received one 275 mg vial of naproxen sodium intramuscularly, while 33 patients were given one vial at the same dosage intravenously. In 56% of the cases complete relief of pain was achieved within 30 minutes of injection, while in 86% pain was completely relieved or greatly decreased within one hour. Side-effects (nausea, vomiting) occurred in three patients, but were linked to a simultaneous aggravation of the ureteral colic.

Effects of acute and chronic treatment with (-)eburnamonine on the tissue supply of oxygen.

Recent research has demonstrated the major role of oxygen in the maintenance of normal cerebral function in the elderly and considerable importance has been attributed to the action of intra-erythrocytic 2-3 diphosphoglycerate (2-3 DPG) in favouring the availability of oxygen to the tissues. This property is reportedly helped or potentiated by the pharmacological action of some eumetabolic vasoregulator drugs. According to numerous clinical trials, (-)eburnamonine possesses this property. A two-part study was carried out in elderly volunteers: a double-blind randomized trial on 20 patients treated acutely (10 with an infusion of 100 mg (-)eburnamonine vs 10 controls) and a within-patients crossover trial on 10 patients treated chronically by the oral route. The results showed a significant increase in the 2-3 DPG values and a beneficial modification of P50 after (-)eburnamonine, probably dependent both on the dose and mode of administration. The effect of the drug was much more marked but more fleeting after acute administration and less intense but more lasting after chronic administration. The latter mode of treatment is of interest in view of the therapeutic effects on several symptoms of senile chronic cerebral insufficiency.

[Clinical and electrophysiologic changes produced by (--) eburnamonine in acute and post-acute stages of head injuries]. / Modificazioni cliniche ed elettrofisiologiche indotte dalla (--) eburnamonina nei traumatizzati cranici in fase acuta e post-acuta.

Two groups of patients suffering from cranial trauma have been submitted to a double-blind acute (1-2 per phlebo ampules/die for 7-10 days) and chronic (1 i.m. ampule for 30 days) at random treatment, respectively with (--) Eburnamonine and Papaverine. The evaluation of the clinical symptoms (state of consciousness, neurologic and post-traumatic symptoms) and of some electrophysiological responses (REG, visual and somato-sensorial evoked potentials) were investigated in basal conditions, during the acute stage, at the end of the chronic treatment and 30 days after the drugs withdrawal. The results showed (--) Eburnamonine to induce a superior improvement than Papaverine of some clinical symptoms (motor disorders, retrograde amnesia, vertigo) and of cortical bioelectrical activity, as rheoencephalographic data and reduction in early latencies of evoked response to somato-sensorial stimulation (SEP) revealed. Local and systemic tolerability was good with both drugs; a slight hypotensive action, more marked with Papaverine, was noted at the end of the treatment.